The new funding round includes collaborations between Israeli and American companies in agriculture, cybersecurity, foodtech, healthcare, mental health, and pharmaceuticals, with an expected total investment of approximately $20 million

WASHINGTON D.C., May 26, 2026 /PRNewswire/ -- On May 5, 2026, the Board of Governors of the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation approved grants totaling $7.5 million for seven new projects between U.S. and Israeli companies. In addition to BIRD funding, the projects will leverage private-sector investment, resulting in a combined investment of $20 million across all projects.

The BIRD Foundation supports strategic collaborations between U.S. and Israeli companies in various technological sectors for joint product development. In addition to providing conditional grants of up to $1.5 million, the Foundation assists companies in identifying strategic partners and facilitating partnerships.

Projects submitted to BIRD are evaluated by BIRD staff and evaluators appointed by the National Institute of Standards and Technology (NIST) of the U.S. Department of Commerce, and the Israel Innovation Authority.

The seven newly approved projects bring the total number of BIRD-supported collaborations to more than 1,200 during the Foundation's 49 years of activity. To date, BIRD's investment of approximately $465 million in joint projects has helped generate direct and indirect revenues of over $10 billion.

The newly approved projects are:

  • Brevel (Kiryat Gat, Israel) and Ayana Bio (Boston, MA) to develop scalable plant cell cultivation using illuminated fermentation technology for the production of plant-based bioactive ingredients.

  • Ensights AI Renewable Energy (Beit Halevi, Israel) and Solitude Labs (West Palm Beach, FL) to develop next-generation cybersecurity solutions for operational technology systems within critical infrastructure

  • Greeneye (Tel Aviv, Israel) and Nutrien Ag Solutions (Loveland, CO) to develop and validate an AI-driven targeted spraying system for agricultural retailers

  • HT Vet (Hod Hasharon, Israel) and VCA Animal Hospitals (Los Angeles, CA) to develop non-invasive skin and subcutaneous tumor screening for cats and expand diagnostic capabilities for dogs through the VISTA IQ platform

  • Identifai-Genetics (Tel Aviv, Israel) and Inocras Inc. (San Diego, CA) to develop the U.S. clinical introduction of a cfDNA-based, genome-wide prenatal test for monogenic disorders

  • Neurogenesis (Givatayim, Israel) and OrganaBio (South Miami, FL) to develop a cell therapy for progressive multiple sclerosis

  • NeuroKaire (Tel Aviv, Israel) and MindfulCare (New York, NY) to develop tailored precision treatments for depression


Source link ← Back to News